{"success":true,"data":{"pressRelease":{"id":"84383","rtpr_id":"nPn4XhNs2a","ticker":"POM","exchange":"NASDAQ","all_tickers":["POM"],"title":"POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare","author":"PR Newswire","published_at":"2026-07-09T12:00:00.778Z","article_body":"POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare\n\nPR Newswire\n\nGUANGZHOU, China, July 9, 2026\n\nGUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the\n\"Company\") (NASDAQ: POM), a digital healthcare company focused on advancing\nAI-enabled healthcare solutions and predictive healthcare capabilities, today\nhighlighted its continued efforts in building an AI-powered chronic disease\nmanagement ecosystem. The Company is integrating artificial intelligence\n(\"AI\"), remote patient monitoring (\"RPM\"), wearable technologies and\nreal-world healthcare data to evolve toward a predictive, continuous and\npersonalized healthcare service provider.\n\nThe Company believes that the global healthcare industry is undergoing a\nsignificant transformation from traditional reactive treatment models toward\nproactive health prediction and long-term disease management, as increasing\nchronic disease prevalence, rapid advancements in AI technologies and broader\nadoption of remote monitoring solutions accelerate the shift.\n\nMultiple market reports released recently have highlighted this industry\ntrend, specifically noting the accelerating adoption of AI-driven healthcare\nand chronic disease management technologies. According to Dimension Market\nResearch, the global AI chronic disease prevention market is projected to grow\nfrom approximately US$30.2 billion in 2026 to US$488.4 billion by 2035,\nrepresenting a compound annual growth rate (\"CAGR\") of 36.2%, driven by\nincreasing demand for AI-driven predictive models and intelligent healthcare\nsolutions across major chronic disease categories.\n\nData Bridge Market Research predicts that the global chronic disease\nmanagement technology market will grow from US$7.21 billion in 2025 to\nUS$15.01 billion by 2033, at a CAGR of 9.6%, driven by growing adoption of\ndigital health technologies, predictive analytics and remote monitoring\nsolutions. Similarly, Allied Market Research also estimates that the global\nchronic disease management industry will increase from US$4.9 billion in 2021\nto US$14.88 billion by 2031, reflecting rising demand for technology-enabled\nchronic disease management solutions.\n\nBuilding an AI-Enabled Predictive Healthcare Ecosystem\n\nAligned with these industry trends, POM continues to strengthen its strategic\nfocus on AI-enabled chronic disease management by integrating healthcare AI\nmodels, wearable technologies, RPM capabilities, physician resources and\nhealthcare payment networks into a connected healthcare ecosystem.\n\nUnlike traditional healthcare models that primarily focus on treatment after\nsymptoms occur, POM aims to support earlier risk identification, continuous\nmonitoring and personalized intervention throughout the healthcare journey.\n\nThe Company continues to develop its healthcare intelligence framework based\non several key components:\n\n * AI Analytics and Predictive Capabilities: Leveraging AI technologies and\nreal-world healthcare data to analyze potential health risks, evaluate patient\ntrends and support more personalized health management.\n * Remote Patient Monitoring and Wearable Integration: Utilizing connected\ndevices and continuous health data collection to extend healthcare management\nbeyond traditional clinical settings.\n * Physician Network and Medical Services: Combining technology-driven insights\nwith professional healthcare resources to provide more effective intervention\nand long-term chronic disease management.\n * Healthcare Ecosystem Partnerships: Exploring collaboration opportunities\nacross healthcare providers, payers and other ecosystem participants to\nsupport more integrated and value-based healthcare services.\nManagement Commentary\n\nMr. Zhenyang Shi, Chairman and Chief Executive Officer of POMDOCTOR,\ncommented: \"The healthcare industry is entering a new era where AI, continuous\nhealth data and connected technologies are accelerating the transformation of\nchronic disease management. With increasing demand for proactive healthcare\nsolutions, we believe AI-powered predictive capabilities and remote monitoring\ntechnologies will play an increasingly important role in improving long-term\nhealth management.\n\n\"At POMDOCTOR, we are building an integrated healthcare ecosystem that\nconnects artificial intelligence, wearable technologies, physician resources,\nhealthcare payment networks and real-world healthcare data. By combining these\ncapabilities, we aim to advance the transition from reactive treatment toward\npredictive, personalized and continuous healthcare management. Looking ahead,\nwe will continue strengthening our technology capabilities, expanding\necosystem partnerships and advancing our vision of building the infrastructure\nfor the future of predictive healthcare.\"\n\nAbout POMDOCTOR LIMITED\n\nPOMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on\nadvancing AI-enabled healthcare solutions and expanding predictive healthcare\ncapabilities. The Company leverages physician resources, wearable\ntechnologies, artificial intelligence, healthcare payment networks and\nreal-world healthcare data to support more personalized, continuous and\ndata-driven healthcare services. Building upon its established healthcare\nplatform and physician network, POM is pursuing the development of a\npredictive healthcare data and services infrastructure designed to improve\nhealthcare outcomes and create long-term value for patients, healthcare\nproviders and other ecosystem participants. For more information, please visit\nthe Company's website: http://ir.7shiliu.com (http://ir.7shiliu.com/) .\n\nForward-Looking Statements\n\nCertain statements in this announcement are forward-looking statements. These\nforward-looking statements involve known and unknown risks and uncertainties\nand are based on the Company's current expectations and projections about\nfuture events that the Company believes may affect its financial condition,\nresults of operations, business strategy and financial needs. Investors can\nfind many (but not all) of these statements by the use of words such as\n\"approximates,\" \"believes,\" \"hopes,\" \"expects,\" \"anticipates,\" \"estimates,\"\n\"projects,\" \"intends,\" \"plans,\" \"will,\" \"would,\" \"should,\" \"could,\" \"may\" or\nother similar expressions. The Company undertakes no obligation to update or\nrevise publicly any forward-looking statements to reflect subsequent occurring\nevents or circumstances, or changes in its expectations, except as may be\nrequired by law. Although the Company believes that the expectations expressed\nin these forward-looking statements are reasonable, it cannot assure you that\nsuch expectations will turn out to be correct, and the Company cautions\ninvestors that actual results may differ materially from the anticipated\nresults and encourages investors to review other factors that may affect its\nfuture results in the Company's filings with the SEC.\n\nFor more information, please contact:\n\nPOMDOCTOR LIMITED\nInvestor Relations Department\nEmail: ir@7lk.com (mailto:ir@7lk.com)\n\nAscent Investor Relations LLC\nTina Xiao\nPhone: +1-646-932-7242\nEmail: investors@ascent-ir.com (mailto:investors@ascent-ir.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/pomdoctor-limited-continues-to-advance-ai-enabled-chronic-disease-management-strategy-amid-growing-demand-for-predictive-healthcare-302821847.html\n(https://www.prnewswire.com/news-releases/pomdoctor-limited-continues-to-advance-ai-enabled-chronic-disease-management-strategy-amid-growing-demand-for-predictive-healthcare-302821847.html)\n\nSOURCE POMDOCTOR LIMITED\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn4XhNs2a","title":"POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare","author":"PR Newswire","ticker":"POM","created":"2026-07-09T12:00:00.778Z","tickers":["POM"],"exchange":"NASDAQ","article_body":"POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare\n\nPR Newswire\n\nGUANGZHOU, China, July 9, 2026\n\nGUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the\n\"Company\") (NASDAQ: POM), a digital healthcare company focused on advancing\nAI-enabled healthcare solutions and predictive healthcare capabilities, today\nhighlighted its continued efforts in building an AI-powered chronic disease\nmanagement ecosystem. The Company is integrating artificial intelligence\n(\"AI\"), remote patient monitoring (\"RPM\"), wearable technologies and\nreal-world healthcare data to evolve toward a predictive, continuous and\npersonalized healthcare service provider.\n\nThe Company believes that the global healthcare industry is undergoing a\nsignificant transformation from traditional reactive treatment models toward\nproactive health prediction and long-term disease management, as increasing\nchronic disease prevalence, rapid advancements in AI technologies and broader\nadoption of remote monitoring solutions accelerate the shift.\n\nMultiple market reports released recently have highlighted this industry\ntrend, specifically noting the accelerating adoption of AI-driven healthcare\nand chronic disease management technologies. According to Dimension Market\nResearch, the global AI chronic disease prevention market is projected to grow\nfrom approximately US$30.2 billion in 2026 to US$488.4 billion by 2035,\nrepresenting a compound annual growth rate (\"CAGR\") of 36.2%, driven by\nincreasing demand for AI-driven predictive models and intelligent healthcare\nsolutions across major chronic disease categories.\n\nData Bridge Market Research predicts that the global chronic disease\nmanagement technology market will grow from US$7.21 billion in 2025 to\nUS$15.01 billion by 2033, at a CAGR of 9.6%, driven by growing adoption of\ndigital health technologies, predictive analytics and remote monitoring\nsolutions. Similarly, Allied Market Research also estimates that the global\nchronic disease management industry will increase from US$4.9 billion in 2021\nto US$14.88 billion by 2031, reflecting rising demand for technology-enabled\nchronic disease management solutions.\n\nBuilding an AI-Enabled Predictive Healthcare Ecosystem\n\nAligned with these industry trends, POM continues to strengthen its strategic\nfocus on AI-enabled chronic disease management by integrating healthcare AI\nmodels, wearable technologies, RPM capabilities, physician resources and\nhealthcare payment networks into a connected healthcare ecosystem.\n\nUnlike traditional healthcare models that primarily focus on treatment after\nsymptoms occur, POM aims to support earlier risk identification, continuous\nmonitoring and personalized intervention throughout the healthcare journey.\n\nThe Company continues to develop its healthcare intelligence framework based\non several key components:\n\n * AI Analytics and Predictive Capabilities: Leveraging AI technologies and\nreal-world healthcare data to analyze potential health risks, evaluate patient\ntrends and support more personalized health management.\n * Remote Patient Monitoring and Wearable Integration: Utilizing connected\ndevices and continuous health data collection to extend healthcare management\nbeyond traditional clinical settings.\n * Physician Network and Medical Services: Combining technology-driven insights\nwith professional healthcare resources to provide more effective intervention\nand long-term chronic disease management.\n * Healthcare Ecosystem Partnerships: Exploring collaboration opportunities\nacross healthcare providers, payers and other ecosystem participants to\nsupport more integrated and value-based healthcare services.\nManagement Commentary\n\nMr. Zhenyang Shi, Chairman and Chief Executive Officer of POMDOCTOR,\ncommented: \"The healthcare industry is entering a new era where AI, continuous\nhealth data and connected technologies are accelerating the transformation of\nchronic disease management. With increasing demand for proactive healthcare\nsolutions, we believe AI-powered predictive capabilities and remote monitoring\ntechnologies will play an increasingly important role in improving long-term\nhealth management.\n\n\"At POMDOCTOR, we are building an integrated healthcare ecosystem that\nconnects artificial intelligence, wearable technologies, physician resources,\nhealthcare payment networks and real-world healthcare data. By combining these\ncapabilities, we aim to advance the transition from reactive treatment toward\npredictive, personalized and continuous healthcare management. Looking ahead,\nwe will continue strengthening our technology capabilities, expanding\necosystem partnerships and advancing our vision of building the infrastructure\nfor the future of predictive healthcare.\"\n\nAbout POMDOCTOR LIMITED\n\nPOMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on\nadvancing AI-enabled healthcare solutions and expanding predictive healthcare\ncapabilities. The Company leverages physician resources, wearable\ntechnologies, artificial intelligence, healthcare payment networks and\nreal-world healthcare data to support more personalized, continuous and\ndata-driven healthcare services. Building upon its established healthcare\nplatform and physician network, POM is pursuing the development of a\npredictive healthcare data and services infrastructure designed to improve\nhealthcare outcomes and create long-term value for patients, healthcare\nproviders and other ecosystem participants. For more information, please visit\nthe Company's website: http://ir.7shiliu.com (http://ir.7shiliu.com/) .\n\nForward-Looking Statements\n\nCertain statements in this announcement are forward-looking statements. These\nforward-looking statements involve known and unknown risks and uncertainties\nand are based on the Company's current expectations and projections about\nfuture events that the Company believes may affect its financial condition,\nresults of operations, business strategy and financial needs. Investors can\nfind many (but not all) of these statements by the use of words such as\n\"approximates,\" \"believes,\" \"hopes,\" \"expects,\" \"anticipates,\" \"estimates,\"\n\"projects,\" \"intends,\" \"plans,\" \"will,\" \"would,\" \"should,\" \"could,\" \"may\" or\nother similar expressions. The Company undertakes no obligation to update or\nrevise publicly any forward-looking statements to reflect subsequent occurring\nevents or circumstances, or changes in its expectations, except as may be\nrequired by law. Although the Company believes that the expectations expressed\nin these forward-looking statements are reasonable, it cannot assure you that\nsuch expectations will turn out to be correct, and the Company cautions\ninvestors that actual results may differ materially from the anticipated\nresults and encourages investors to review other factors that may affect its\nfuture results in the Company's filings with the SEC.\n\nFor more information, please contact:\n\nPOMDOCTOR LIMITED\nInvestor Relations Department\nEmail: ir@7lk.com (mailto:ir@7lk.com)\n\nAscent Investor Relations LLC\nTina Xiao\nPhone: +1-646-932-7242\nEmail: investors@ascent-ir.com (mailto:investors@ascent-ir.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/pomdoctor-limited-continues-to-advance-ai-enabled-chronic-disease-management-strategy-amid-growing-demand-for-predictive-healthcare-302821847.html\n(https://www.prnewswire.com/news-releases/pomdoctor-limited-continues-to-advance-ai-enabled-chronic-disease-management-strategy-amid-growing-demand-for-predictive-healthcare-302821847.html)\n\nSOURCE POMDOCTOR LIMITED\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-07-09T12:00:01.05257168Z","server_sent_at_ms":1783598401052},"received_at":"2026-07-09T12:00:01.124Z","source_url":"https://www.prnewswire.com/news-releases/pomdoctor-limited-continues-to-advance-ai-enabled-chronic-disease-management-strategy-amid-growing-demand-for-predictive-healthcare-302821847.html"},"analysis":{"id":"73446","press_release_id":"84383","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"POMDOCTOR LIMITED issued a strategic update reiterating its focus on building an AI-enabled chronic disease management ecosystem.\n\nThe release cites third-party market research projecting significant growth in AI-driven healthcare and chronic disease management technologies through 2035.\n\nCEO Zhenyang Shi commented on the industry shift toward proactive health prediction, but the company announced no new products, partnerships, or financial results.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine strategic update with no new material developments; suppress."},"keyFigures":{"customDimensions":{"ai_chronic_disease_cagr":"36.2%","chronic_disease_tech_cagr":"9.6%","ai_chronic_disease_market_2026":"30.2 billion","ai_chronic_disease_market_2035":"488.4 billion","chronic_disease_tech_market_2025":"7.21 billion","chronic_disease_tech_market_2033":"15.01 billion"}},"quotedText":"The healthcare industry is entering a new era where AI, continuous health data and connected technologies are accelerating the transformation of chronic disease management.","namedEntities":{"people":[{"name":"Zhenyang Shi","role":"Chairman and Chief Executive Officer"},{"name":"Tina Xiao","role":"Investor Relations Contact"}],"products":[],"companies":[{"name":"POMDOCTOR LIMITED","ticker":"POM"},{"name":"Dimension Market Research","relationship":"market research firm"},{"name":"Data Bridge Market Research","relationship":"market research firm"},{"name":"Allied Market Research","relationship":"market research firm"},{"name":"Ascent Investor Relations LLC","relationship":"investor relations firm"}],"dollarAmounts":[{"amount":"US$30.2 billion","context":"projected global AI chronic disease prevention market in 2026"},{"amount":"US$488.4 billion","context":"projected global AI chronic disease prevention market in 2035"},{"amount":"US$7.21 billion","context":"projected global chronic disease management technology market in 2025"},{"amount":"US$15.01 billion","context":"projected global chronic disease management technology market in 2033"},{"amount":"US$4.9 billion","context":"global chronic disease management industry in 2021"},{"amount":"US$14.88 billion","context":"projected global chronic disease management industry in 2031"}]},"materialImpact":{"score":1,"reasoning":"This is a boilerplate strategic update highlighting industry tailwinds and the company's general vision. It contains no new product launches, specific partnership announcements, financial results, or concrete operational milestones. The cited market data is from third-party research firms, not the filer."},"tickerRelevance":{"others":[],"primary":"POM"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"boilerplate-strategic-update","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"POMDOCTOR LIMITED issued a strategic update reiterating its focus on building an AI-enabled chronic disease management ecosystem.\n\nThe release cites third-party market research projecting significant growth in AI-driven healthcare and chronic disease management technologies through 2035.\n\nCEO Zhenyang Shi commented on the industry shift toward proactive health prediction, but the company announced no new products, partnerships, or financial results.","key_figures":{"customDimensions":{"ai_chronic_disease_cagr":"36.2%","chronic_disease_tech_cagr":"9.6%","ai_chronic_disease_market_2026":"30.2 billion","ai_chronic_disease_market_2035":"488.4 billion","chronic_disease_tech_market_2025":"7.21 billion","chronic_disease_tech_market_2033":"15.01 billion"}},"named_entities":{"people":[{"name":"Zhenyang Shi","role":"Chairman and Chief Executive Officer"},{"name":"Tina Xiao","role":"Investor Relations Contact"}],"products":[],"companies":[{"name":"POMDOCTOR LIMITED","ticker":"POM"},{"name":"Dimension Market Research","relationship":"market research firm"},{"name":"Data Bridge Market Research","relationship":"market research firm"},{"name":"Allied Market Research","relationship":"market research firm"},{"name":"Ascent Investor Relations LLC","relationship":"investor relations firm"}],"dollarAmounts":[{"amount":"US$30.2 billion","context":"projected global AI chronic disease prevention market in 2026"},{"amount":"US$488.4 billion","context":"projected global AI chronic disease prevention market in 2035"},{"amount":"US$7.21 billion","context":"projected global chronic disease management technology market in 2025"},{"amount":"US$15.01 billion","context":"projected global chronic disease management technology market in 2033"},{"amount":"US$4.9 billion","context":"global chronic disease management industry in 2021"},{"amount":"US$14.88 billion","context":"projected global chronic disease management industry in 2031"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-09T12:05:31.838Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"boilerplate-strategic-update","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":null,"modelName":"george-droid-qwen-72b"}}